… , and smoking cessation) or treatments provided to all participants (breath retraining, long-acting
beta-agonist/long-acting muscarinic antagonist use, provision of a written action plan) …

… long-acting bronchodilators). Adherence underpins successful pharmacotherapy of all …
evaluated the treatable traits that predict lung function and quality of life decline in a COPD cohort, …

… to predict responses to inhaled corticosteroids (ICS) in COPD … long-acting bronchodilators
with or without ICS has involved some landmark randomized controlled trials in COPD patients…

… Baseline characteristics were assessed in the baseline period before the index … -bronchodilator
forced expiratory volume in 1 second [FEV 1 ] and pre-bronchodilator FEV 1 % predicted) …

… This post hoc analysis of the “Early MAXimization of bronchodilation for improving COPD
stability” (EMAX) trial investigated whether patients achieving early clinically important …

… options with long-acting bronchodilators in patients with severe COPD, the following … predict
length of survival when patients are screened. In COPD patients, evaluating treatable traits …

… Long-acting bronchodilators should be used as the first pharmacologic step in the treatment
of all patients with COPD … of choice in stable COPD patients with chronic hypercapnic …

… of long-acting bronchodilators (LABDs), with different pharmacologic targets. Long-acting …
of acetylcholine at muscarinic receptors, whereas long-acting beta-2 adrenoreceptor agonists (…

… predictive factors of response to treatment with single bronchodilation monotherapy in patients
… document recommends the use of a single long-acting bronchodilator (LABD) to initiate …

… In COPD, evidence from large randomized controlled trials … (including inhaled long
acting bronchodilators and … independent predictor of risk of exacerbations, and treatment …